Alicia Irurzun-Lafitte has departed from a principal position at M Ventures for a partner role at another pharmaceutical firm's corporate venturing fund, UCB Ventures.

Alicia Irurzun-Lafitte, formerly a principal at M Ventures, the corporate venture capital unit for Germany-based drugs producer Merck Group, has joined UCB Ventures, Belgium-based biopharmaceutical company UCB’s corporate venturing subsidiary, as a partner. UCB Ventures is a €150m ($168m) fund launched in 2017 that invests in early-stage startups developing therapeutics focused on immunological aspects of…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.